Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXACT-CABG study of XC001 in coronary artery disease patients undergoing CABG
NL-OMON60491Phase 2Completed
- Sponsor
- XyloCor Therapeutics
- Start
- Sep 2025
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of encoberminogene rezmadenovec in coronary arteriosclerosis, angina pectoris and left ventricular systolic dysfunction (LVSD), sponsored by XyloCor Therapeutics. Primary endpoint: Proportion of qualifying treated myocardial segments improving on CMR at Week 12 and/or Week 26. Started Sep 2025; status: completed.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
coronary arteriosclerosisangina pectorisleft ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on NL-OMON60491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60491.